JP6442291B2 - Particle dispersion, kit for use in detection of target substance, and target substance detection method - Google Patents

Particle dispersion, kit for use in detection of target substance, and target substance detection method Download PDF

Info

Publication number
JP6442291B2
JP6442291B2 JP2015001216A JP2015001216A JP6442291B2 JP 6442291 B2 JP6442291 B2 JP 6442291B2 JP 2015001216 A JP2015001216 A JP 2015001216A JP 2015001216 A JP2015001216 A JP 2015001216A JP 6442291 B2 JP6442291 B2 JP 6442291B2
Authority
JP
Japan
Prior art keywords
mass
particle dispersion
target substance
reagent
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015001216A
Other languages
Japanese (ja)
Other versions
JP2016125948A (en
Inventor
博之 本間
博之 本間
田守 功二
功二 田守
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JSR Corp
JSR Life Sciences Corp
Original Assignee
JSR Corp
JSR Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JSR Corp, JSR Life Sciences Corp filed Critical JSR Corp
Priority to JP2015001216A priority Critical patent/JP6442291B2/en
Publication of JP2016125948A publication Critical patent/JP2016125948A/en
Application granted granted Critical
Publication of JP6442291B2 publication Critical patent/JP6442291B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Description

本発明は、粒子分散液、標的物質の検出に用いるためのキット、及び標的物質の検出方法に関する。   The present invention relates to a particle dispersion, a kit for use in detecting a target substance, and a method for detecting a target substance.

抗原抗体反応を利用した免疫凝集法が、臨床検査、生化学研究等の種々の分野で広く活用されている。とりわけ、ラテックス凝集法に代表される担体を用いる免疫凝集法は、担体を使用せずに凝集反応を検出する方法に比べて検出感度等が良好であるため、免疫凝集法の主流となっている。   An immunoagglutination method using an antigen-antibody reaction is widely used in various fields such as clinical examination and biochemical research. In particular, immunoaggregation methods using carriers typified by latex agglutination methods are the mainstream of immunoagglutination methods because they have better detection sensitivity and the like than methods that detect agglutination without using carriers. .

しかしながら、免疫凝集法は、化学発光免疫測定法等の他の測定方法と比較すると検出感度が不充分であると指摘されることがある。
そのため、免疫凝集促進剤として、ポリエチレングリコール等の水溶性高分子が用いられているが(特許文献1及び2)が、更なる検出感度の改善が望まれている。
However, it may be pointed out that the immunoagglutination method has insufficient detection sensitivity as compared with other measurement methods such as chemiluminescence immunoassay.
Therefore, water-soluble polymers such as polyethylene glycol are used as immune aggregation promoters (Patent Documents 1 and 2), but further improvement in detection sensitivity is desired.

特開平08−278308号公報Japanese Patent Laid-Open No. 08-278308 特開2003−294753号公報JP 2003-294753 A

したがって、本発明が解決しようとする課題は、免疫凝集法による検体中の標的物質の検出を高感度化する新たな技術を提供することにある。   Therefore, the problem to be solved by the present invention is to provide a new technique for increasing the sensitivity of detection of a target substance in a specimen by immunoagglutination.

そこで、本発明者らは鋭意検討した結果、水性媒体を分散媒とする担体粒子の粒子分散液中にナフタレン骨格を有する低分子化合物を含有せしめ、これを用いて免疫凝集法による検出を行うことによって、検体中の標的物質の検出を高感度化できることを見出し、本発明を完成した。   Therefore, as a result of intensive studies, the present inventors have incorporated a low molecular weight compound having a naphthalene skeleton into a particle dispersion of carrier particles using an aqueous medium as a dispersion medium, and use this to perform detection by immunoaggregation. Thus, it has been found that detection of a target substance in a specimen can be made highly sensitive, and the present invention has been completed.

すなわち、本発明は、以下の〔1〕〜〔3〕を提供するものである。   That is, the present invention provides the following [1] to [3].

〔1〕水性媒体を分散媒とする担体粒子の粒子分散液であって、ナフタレン骨格を有する低分子化合物を含有する、粒子分散液(以下、「本発明の粒子分散液」とも称する)。   [1] A particle dispersion of carrier particles using an aqueous medium as a dispersion medium and containing a low molecular compound having a naphthalene skeleton (hereinafter also referred to as “particle dispersion of the present invention”).

〔2〕免疫凝集法による検体中の標的物質の検出に用いるためのキットであって、上記〔1〕の粒子分散液を備える、キット(以下、「本発明のキット」とも称する)。   [2] A kit for use in detection of a target substance in a specimen by an immunoagglutination method, comprising the particle dispersion of [1] above (hereinafter also referred to as “kit of the present invention”).

〔3〕免疫凝集法による検体中の標的物質の検出方法であって、標的物質と結合可能な物質が担持された担体粒子と、検体とを、ナフタレン骨格を有する低分子化合物の存在下で接触させる工程を含むことを特徴とする、検出方法(以下、「本発明の検出方法」とも称する)。   [3] A method for detecting a target substance in a specimen by immunoagglutination, wherein the carrier particle carrying a substance capable of binding to the target substance is contacted with the specimen in the presence of a low molecular compound having a naphthalene skeleton. A detection method (hereinafter, also referred to as “detection method of the present invention”).

本発明によれば、免疫凝集法による検体中の標的物質の検出を高感度化できる。   ADVANTAGE OF THE INVENTION According to this invention, the detection of the target substance in the sample by an immunoagglutination method can be made highly sensitive.

〔粒子分散液〕
本発明の水性媒体を分散媒とする担体粒子の粒子分散液は、ナフタレン骨格を有する低分子化合物を含有するものである。
[Particle dispersion]
The particle dispersion of carrier particles using the aqueous medium of the present invention as a dispersion medium contains a low molecular compound having a naphthalene skeleton.

<ナフタレン骨格を有する低分子化合物>
ナフタレン骨格を有する低分子化合物は、ナフタレン骨格を有する非ビニル系低分子化合物の他、ナフタレン骨格を有するビニル系低分子化合物、当該化合物のオリゴマーを含む概念である。ナフタレン骨格を有する低分子化合物としては、アセチルナフタレン、ナフトアルデヒド、エチルナフタレン、プロピルナフタレン、ビニルナフタレン、(メタ)アクリル酸ナフチルが好ましい。アセチルナフタレンとしては、1−アセチルナフタレン、2−アセチルナフタレンが挙げられる。ナフトアルデヒドとしては、1−ナフトアルデヒド、2−ナフトアルデヒドが挙げられる。エチルナフタレンとしては、1−エチルナフタレン、2−エチルナフタレンが挙げられる。プロピルナフタレンとしては、1−プロピルナフタレン、2−プロピルナフタレンが挙げられる。ビニルナフタレンとしては、1−ビニルナフタレン、2−ビニルナフタレンが挙げられる。(メタ)アクリル酸ナフチルとしては、(メタ)アクリル酸1−ナフチル、(メタ)アクリル酸2−ナフチルが挙げられる。
これらの中でも、ナフタレン骨格を有する低分子化合物としては、検出感度の観点から、アセチルナフタレンが特に好ましい。
なお、本発明の粒子分散液は、ナフタレン骨格を有する低分子化合物のうち1種を単独で含んでいてもよく、2種以上を組み合わせて含んでいてもよい。
<Low molecular compound having naphthalene skeleton>
The low molecular compound having a naphthalene skeleton is a concept including a non-vinyl low molecular compound having a naphthalene skeleton, a vinyl low molecular compound having a naphthalene skeleton, and an oligomer of the compound. As the low molecular weight compound having a naphthalene skeleton, acetylnaphthalene, naphthaldehyde, ethylnaphthalene, propylnaphthalene, vinylnaphthalene, and naphthyl (meth) acrylate are preferable. Examples of acetylnaphthalene include 1-acetylnaphthalene and 2-acetylnaphthalene. Examples of naphthaldehyde include 1-naphthaldehyde and 2-naphthaldehyde. Examples of ethylnaphthalene include 1-ethylnaphthalene and 2-ethylnaphthalene. Examples of propylnaphthalene include 1-propylnaphthalene and 2-propylnaphthalene. Examples of vinyl naphthalene include 1-vinyl naphthalene and 2-vinyl naphthalene. Examples of (meth) acrylic acid naphthyl include (meth) acrylic acid 1-naphthyl and (meth) acrylic acid 2-naphthyl.
Among these, acetylnaphthalene is particularly preferable as a low molecular compound having a naphthalene skeleton from the viewpoint of detection sensitivity.
In addition, the particle dispersion liquid of the present invention may contain one kind of low molecular compounds having a naphthalene skeleton, or may contain two or more kinds in combination.

ナフタレン骨格を有する低分子化合物の含有量は、検出感度、及び抗原抗体反応によるラテックス粒子の凝集能等の観点から、担体粒子固形分100質量部に対して、好ましくは0.001質量部以上、より好ましくは0.005質量部以上、更に好ましくは0.01質量部以上、更に好ましくは0.05質量部以上、特に好ましくは0.1質量部以上であり、また、保存安定性の観点や低含量で高感度化する観点等から、担体粒子固形分100質量部に対して、好ましくは10質量部以下、より好ましくは5質量部以下、更に好ましくは3質量部以下、特に好ましくは1.5質量部以下である。このような範囲とすることにより、検出感度の向上と保存安定性の改善を両立できる。   The content of the low molecular compound having a naphthalene skeleton is preferably 0.001 part by mass or more with respect to 100 parts by mass of the carrier particle solid content from the viewpoint of detection sensitivity and the ability of latex particles to aggregate due to the antigen-antibody reaction More preferably 0.005 parts by mass or more, still more preferably 0.01 parts by mass or more, still more preferably 0.05 parts by mass or more, and particularly preferably 0.1 parts by mass or more. From the viewpoint of increasing the sensitivity with a low content, etc., the amount is preferably 10 parts by mass or less, more preferably 5 parts by mass or less, still more preferably 3 parts by mass or less, particularly preferably 1. 5 parts by mass or less. By setting it as such a range, the improvement of detection sensitivity and the improvement of storage stability can be made compatible.

また、ナフタレン骨格を有する低分子化合物の含有量は、粒子分散液全量に対しては、好ましくは0.5×10-10質量%以上、より好ましくは1×10-10質量%以上、更に好ましくは0.5×10-8質量%以上、更に好ましくは1×10-8質量%以上、更に好ましくは1×10-7質量%以上、更に好ましくは1×10-6質量%以上であり、また、好ましくは1質量%以下、より好ましくは1×10-1質量%以下、更に好ましくは0.5×10-1質量%以下である。そして、粒子分散液を凝集試薬製造用粒子分散液とする場合は、1×10-10〜1×10-1質量%が好ましく、1×10-8〜0.5×10-1質量%がより好ましく、1×10-6〜0.5×10-1質量%が特に好ましい。一方、粒子分散液を凝集試薬とする場合は、0.5×10-10〜0.5×10-1質量%が好ましく、0.5×10-8〜1×10-2質量%がより好ましい。0.5×10-6〜0.5×10-2質量%が特に好ましい。 In addition, the content of the low molecular weight compound having a naphthalene skeleton is preferably 0.5 × 10 −10 mass% or more, more preferably 1 × 10 −10 mass% or more, and still more preferably based on the total amount of the particle dispersion. Is 0.5 × 10 −8 mass% or more, more preferably 1 × 10 −8 mass% or more, more preferably 1 × 10 −7 mass% or more, and further preferably 1 × 10 −6 mass% or more. Further, it is preferably 1% by mass or less, more preferably 1 × 10 −1 % by mass or less, and further preferably 0.5 × 10 −1 % by mass or less. When the particle dispersion is used as a particle dispersion for producing an agglutinating reagent, 1 × 10 −10 to 1 × 10 −1 mass% is preferable, and 1 × 10 −8 to 0.5 × 10 −1 mass% is preferable. More preferably, 1 × 10 −6 to 0.5 × 10 −1 mass% is particularly preferable. On the other hand, when the particle dispersion is used as an agglutinating reagent, 0.5 × 10 −10 to 0.5 × 10 −1 mass% is preferable, and 0.5 × 10 −8 to 1 × 10 −2 mass% is more preferable. preferable. 0.5 × 10 −6 to 0.5 × 10 −2 mass% is particularly preferable.

ナフタレン骨格を有する低分子化合物の含有量は、例えば次の方法により測定することができる。すなわち、ナフタレン骨格を有する低分子化合物を含む粒子分散液を限外濾過することにより、分散媒成分を除去した後、粒子に吸着したナフタレン骨格を有する低分子化合物を、熱分析ガスクロマトグラフ/質量分析装置(PyGC/MS)(MS:JMS−600H(日本電子社製)、GC:Agilent6890N、パイオライザー:PY−2020D フロンティアラボ)を用いて、以下の条件で測定することで、ナフタレン骨格を有する低分子化合物の含有量を測定することができる。
(測定条件)
熱分解温度:600℃
カラム:SPB−5(SPELCO)
キャリアガス:He 1mL/min
The content of the low molecular compound having a naphthalene skeleton can be measured, for example, by the following method. That is, the dispersion liquid component is removed by ultrafiltration of a particle dispersion containing a low molecular compound having a naphthalene skeleton, and then the low molecular compound having a naphthalene skeleton adsorbed on the particles is subjected to thermal analysis gas chromatography / mass spectrometry. By using an apparatus (PyGC / MS) (MS: JMS-600H (manufactured by JEOL Ltd.), GC: Agilent 6890N, Piolizer: PY-2020D Frontier Lab), a low level having a naphthalene skeleton is measured under the following conditions. The content of the molecular compound can be measured.
(Measurement condition)
Thermal decomposition temperature: 600 ° C
Column: SPB-5 (SPELCO)
Carrier gas: He 1mL / min

<担体粒子>
担体粒子は、不溶性担体粒子であれば特に限定されないが、免疫ラテックス凝集測定に適したものとする観点から、ラテックス粒子が好ましい。
また、担体粒子としては、合成高分子系又は天然高分子系のポリマー粒子が好ましく、アリール基を有するモノマーを含むモノマー成分に由来するポリマー粒子がより好ましい。
アリール基を有するモノマー(以下、モノマー(a)とも称する)としては、フェニル基を有するモノマー、ナフチル基を有するモノマーが挙げられ、1種を単独で用いてもよく、2種以上を組み合わせて用いてもよい。フェニル基を有するモノマーとしては、スチレン系モノマーが好ましい。フェニル基を有するモノマーの具体例としては、スチレン、アミノスチレン、2−メチルスチレン、4−メチルスチレン、4−クロロスチレン、4−ビニル安息香酸、ジビニルベンゼン、ビニルトルエン等が挙げられる。また、ナフチル基を有するモノマーとしては、ナフチル基を有する不飽和モノマーが好ましい。ナフチル基を有するモノマーの具体例としては、1−ビニルナフタレン、2−ビニルナフタレン、(メタ)アクリル酸1−ナフチル、(メタ)アクリル酸2−ナフチル等が挙げられる。
モノマー(a)の含有量は、モノマー成分全量に対して、好ましくは70〜100質量%、より好ましくは90〜99.8質量%であり、特に好ましくは95〜99.5質量%である。
<Carrier particles>
The carrier particles are not particularly limited as long as they are insoluble carrier particles, but latex particles are preferable from the viewpoint of being suitable for immunolatex aggregation measurement.
Further, as the carrier particles, synthetic polymer type or natural polymer type polymer particles are preferable, and polymer particles derived from a monomer component containing a monomer having an aryl group are more preferable.
Examples of the monomer having an aryl group (hereinafter, also referred to as monomer (a)) include a monomer having a phenyl group and a monomer having a naphthyl group. One type may be used alone, or two or more types may be used in combination. May be. As the monomer having a phenyl group, a styrene monomer is preferable. Specific examples of the monomer having a phenyl group include styrene, aminostyrene, 2-methylstyrene, 4-methylstyrene, 4-chlorostyrene, 4-vinylbenzoic acid, divinylbenzene, vinyltoluene and the like. Moreover, as a monomer which has a naphthyl group, the unsaturated monomer which has a naphthyl group is preferable. Specific examples of the monomer having a naphthyl group include 1-vinylnaphthalene, 2-vinylnaphthalene, 1-naphthyl (meth) acrylate, 2-naphthyl (meth) acrylate, and the like.
The content of the monomer (a) is preferably 70 to 100% by mass, more preferably 90 to 99.8% by mass, and particularly preferably 95 to 99.5% by mass with respect to the total amount of the monomer components.

また、上記モノマー(a)以外のモノマー(以下、モノマー(b)とも称する)としては、(メタ)アクリル酸、イタコン酸、無水マレイン酸、クロトン酸等の不飽和カルボン酸モノマー又は不飽和無水カルボン酸モノマー;2−アクリルアミド−2−メチルプロパンスルホン酸、イソプレンスルホン酸、スチレンスルホン酸、ジビニルベンゼンスルホン酸、2−メチルスチレンスルホン酸、4−メチルスチレンスルホン酸、これらの塩等の不飽和スルホン酸モノマー又はその塩;(メタ)アクリルアミド、N−ヒドロキシエチル(メタ)アクリルアミド、N,N−ジメチル(メタ)アクリルアミド、N−イソプロプル(メタ)アクリルアミド、(メタ)アクリロイルモルホリン、N,N−ジメチルアミノプロピルアクリルアミド、N,N−ジメチルアミノプロピルアクリルアミドのメチルクロライド4級塩、ダイアセトンアクリルアミド、N−ビニルアセトアミド等の(メタ)アクリルアミドモノマー;(メタ)アクリル酸メトキシエチル、(メタ)アクリル酸メチル、(メタ)アクリル酸エチル、(メタ)アクリル酸プロピル、(メタ)アクリル酸ラウリル、(メタ)アクリル酸シクロヘキシル、(メタ)アクリル酸イソボルニル、(メタ)アクリル酸ベンジル、グリセロール(メタ)クリレート、ポリエチレングリコール(メタ)アクリレート、2−ヒドロキシエチル(メタ)アクリレート等の(メタ)アクリレートモノマー;アクロレイン等の不飽和アルデヒドモノマーの他、アリルアミン、N−ビニル−2−ピロリドン等が挙げられ、1種を単独で用いてもよく、2種以上を組み合わせて用いてもよい。
これらの中でも、モノマー(b)としては、不飽和カルボン酸モノマー、不飽和無水カルボン酸モノマー、不飽和スルホン酸モノマー又はその塩が好ましい。なお、不飽和スルホン酸モノマーの塩は特に限定されるものではなく、ナトリウム塩、カリウム塩、リチウム塩等のアルカリ金属塩;カルシウム塩等のアルカリ土類金属塩;アンモニウム塩等が挙げられる。
モノマー(b)の含有量は、モノマー成分全量に対して、好ましくは0〜30質量%、より好ましくは0.2〜10質量%であり、特に好ましくは0.5〜5質量%である。
Moreover, as monomers other than the monomer (a) (hereinafter also referred to as monomer (b)), unsaturated carboxylic acid monomers such as (meth) acrylic acid, itaconic acid, maleic anhydride and crotonic acid, or unsaturated carboxylic anhydrides Acid monomer; unsaturated sulfonic acid such as 2-acrylamido-2-methylpropanesulfonic acid, isoprenesulfonic acid, styrenesulfonic acid, divinylbenzenesulfonic acid, 2-methylstyrenesulfonic acid, 4-methylstyrenesulfonic acid, and salts thereof Monomer or salt thereof; (meth) acrylamide, N-hydroxyethyl (meth) acrylamide, N, N-dimethyl (meth) acrylamide, N-isopropyl (meth) acrylamide, (meth) acryloylmorpholine, N, N-dimethylaminopropyl Acrylamide, N, N- (Meth) acrylamide monomers such as methyl chloride quaternary salt of methylaminopropylacrylamide, diacetone acrylamide, N-vinylacetamide; methoxyethyl (meth) acrylate, methyl (meth) acrylate, ethyl (meth) acrylate, ( Propyl (meth) acrylate, lauryl (meth) acrylate, cyclohexyl (meth) acrylate, isobornyl (meth) acrylate, benzyl (meth) acrylate, glycerol (meth) acrylate, polyethylene glycol (meth) acrylate, 2-hydroxy (Meth) acrylate monomers such as ethyl (meth) acrylate; unsaturated aldehyde monomers such as acrolein, as well as allylamine, N-vinyl-2-pyrrolidone, and the like. It may be used in combination.
Among these, as the monomer (b), an unsaturated carboxylic acid monomer, an unsaturated carboxylic anhydride monomer, an unsaturated sulfonic acid monomer, or a salt thereof is preferable. The salt of the unsaturated sulfonic acid monomer is not particularly limited, and examples thereof include alkali metal salts such as sodium salt, potassium salt and lithium salt; alkaline earth metal salts such as calcium salt; ammonium salt and the like.
The content of the monomer (b) is preferably 0 to 30% by mass, more preferably 0.2 to 10% by mass, and particularly preferably 0.5 to 5% by mass with respect to the total amount of the monomer components.

担体粒子の平均粒径は特に限定されないが、検出感度や製造コストの観点から、好ましくは0.01〜1μm、より好ましくは0.02〜0.75μm、特に好ましくは0.05〜0.5μmである。本明細書において平均粒径は、体積平均粒径を意味し、実施例と同様にして測定した値を云うものとする。   The average particle size of the carrier particles is not particularly limited, but is preferably 0.01 to 1 μm, more preferably 0.02 to 0.75 μm, and particularly preferably 0.05 to 0.5 μm from the viewpoint of detection sensitivity and production cost. It is. In the present specification, the average particle diameter means a volume average particle diameter, and is a value measured in the same manner as in the examples.

担体粒子は、標的物質と結合可能な物質が担持されたものでも、標的物質と結合可能な物質が担持されていないものでもよい。標的物質と結合可能な物質としては、標的物質に対する抗原又は抗体が好ましい。例えば、レセプター、酵素、血中タンパク、感染症関連抗原、微生物、ウイルス、ホルモン、環境関係物質(例えば、環境ホルモン等)等の抗原や、これら抗原に対する抗体等が挙げられる。当該抗体は、特定の抗原に対する結合性を有すればよく、抗体のフラグメントも含まれる。
具体的には、抗アンチプラスミン抗体、抗Dダイマー抗体、抗FDP抗体、抗tPA抗体、抗トロンビン・アンチトロンビン複合体抗体、抗FPA抗体等の凝固線溶関連検査用抗体又はこれに対する抗原;抗BFP抗体、抗CEA抗体、抗AFP抗体、抗TSH抗体、抗フェリチン抗体、抗CA19−9抗体等の腫瘍関連検査用抗体又はこれに対する抗原;抗アポリポタンパク抗体、抗β2−ミクロブロブリン抗体、抗α1―ミクログロブリン抗体、抗免疫グロブリン抗体、抗CRP抗体等の血清蛋白関連検査用抗体又はこれに対する抗原;抗HCG抗体等の内分泌機能検査用抗体又はこれに対する抗原;抗ジゴキシン抗体、抗リドカイン抗体等の薬物分析用抗体又はこれに対する抗原;HBs抗原、HCV抗原、HIV−1抗原、HIV−2抗原、HTLV−1抗原、マイコプラズマ抗原、トキソプラズマ抗原、ストレプトリジンO抗原等の感染症関連検査用抗原又はこれに対する抗体;DNA抗原、熱変成ヒトIgG等の自己免疫関連検査用抗原又はこれに対する抗体等が挙げられる。なお、抗体は、ポリクローナル抗体でもモノクローナル抗体でもよい。
なお、標的物質と結合可能な物質の担体粒子への担持は、疎水−疎水相互作用による物理吸着、水溶性カルボジイミド系縮合剤等を用いた化学結合等の常法に従って行えばよい。
The carrier particles may be those on which a substance that can bind to the target substance is supported or those that do not support a substance that can bind to the target substance. As the substance capable of binding to the target substance, an antigen or antibody against the target substance is preferable. Examples thereof include antigens such as receptors, enzymes, blood proteins, infectious disease-related antigens, microorganisms, viruses, hormones, and environmental substances (for example, environmental hormones), antibodies against these antigens, and the like. The antibody only needs to have a binding property to a specific antigen, and includes a fragment of the antibody.
Specifically, antibodies for coagulation / fibrinolysis related tests such as anti-antiplasmin antibodies, anti-D dimer antibodies, anti-FDP antibodies, anti-tPA antibodies, anti-thrombin / antithrombin complex antibodies, anti-FPA antibodies or antigens therefor; BFP antibody, anti-CEA antibody, anti-AFP antibody, anti-TSH antibody, anti-ferritin antibody, anti-CA19-9 antibody and other tumor-related test antibodies or antigens thereto; anti-apolipoprotein antibody, anti-β2-microbrovulin antibody, anti-antibody Antibody for serum protein-related test such as α1-microglobulin antibody, anti-immunoglobulin antibody, anti-CRP antibody or the antigen thereto; antibody for endocrine function test such as anti-HCG antibody or the antigen thereto; anti-digoxin antibody, anti-lidocaine antibody, etc. Antibodies for drug analysis or antigens thereto; HBs antigen, HCV antigen, HIV-1 antigen, HIV-2 Antigens for infectious disease-related tests such as antigens, HTLV-1 antigens, mycoplasma antigens, toxoplasma antigens, streptridine O antigens or antibodies thereto; antigens for autoimmune-related tests such as DNA antigens, heat-denatured human IgG, or antibodies thereto Is mentioned. The antibody may be a polyclonal antibody or a monoclonal antibody.
In addition, what is necessary is just to carry | support to the support particle of the substance which can be couple | bonded with a target substance in accordance with conventional methods, such as physical adsorption by hydrophobic-hydrophobic interaction, chemical bonding using a water-soluble carbodiimide type condensing agent, etc.

また、担体粒子は、ブロッキング剤がコーティングされたものでもよい。ブロッキング剤は、非特異反応をブロッキングできるものであれば特に限定されないが、牛血清アルブミン等の生体由来の水溶性ポリマーや化学合成した水溶性ポリマー等が挙げられる。
なお、ブロッキング剤のコーティングは、ブロッキング剤を含む溶液中に粒子を分散させた後、遠心分離を行い、上澄み液を除去し再度粒子を水又は緩衝液により再分散させる等の常法に従って行えばよい。
The carrier particles may be coated with a blocking agent. The blocking agent is not particularly limited as long as it can block a non-specific reaction, and examples thereof include biologically derived water-soluble polymers such as bovine serum albumin and chemically synthesized water-soluble polymers.
The coating of the blocking agent may be performed according to a conventional method such as dispersing the particles in a solution containing the blocking agent, then centrifuging, removing the supernatant, and redispersing the particles again with water or a buffer solution. Good.

担体粒子の含有量(固形分換算)は、粒子分散液全量に対して、好ましくは0.001質量%以上、より好ましくは0.005質量%以上、更に好ましくは0.01質量%以上、更に好ましくは0.05質量%以上であり、また、好ましくは50質量%以下、より好ましくは40質量%以下、更に好ましくは30質量%以下、更に好ましくは20質量%以下、更に好ましくは15質量%以下である。そして、粒子分散液を凝集試薬製造用粒子分散液とする場合は、0.1〜20質量%が好ましく、0.1〜15質量%がより好ましく、0.1〜10質量%が特に好ましい。一方、粒子分散液を凝集試薬とする場合は、0.005〜5質量%が好ましく、0.01〜2質量%が特に好ましい。   The content of the carrier particles (in terms of solid content) is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, still more preferably 0.01% by mass or more, based on the total amount of the particle dispersion. Preferably it is 0.05% by mass or more, preferably 50% by mass or less, more preferably 40% by mass or less, still more preferably 30% by mass or less, still more preferably 20% by mass or less, and further preferably 15% by mass. It is as follows. And when making a particle dispersion into the particle dispersion for agglutination reagent manufacture, 0.1-20 mass% is preferable, 0.1-15 mass% is more preferable, 0.1-10 mass% is especially preferable. On the other hand, when the particle dispersion is used as an agglutinating reagent, 0.005 to 5% by mass is preferable, and 0.01 to 2% by mass is particularly preferable.

<水性媒体>
水性媒体は、担体粒子を分散できるものであればよいが、水を含むものが好ましい。水の含有量は、水性媒体全量に対して、好ましくは40〜100質量%、より好ましくは60〜100質量%、更に好ましくは80〜100質量%、特に好ましくは90〜100質量%である。
また、水性媒体は、グッド緩衝液、トリス緩衝液、リン酸緩衝液、グリシン緩衝液、アンモニア緩衝液等の緩衝液であってもよい。
なお、水性媒体は、水や緩衝液の他に、メタノール、エタノール、イソプロパノール等の低級アルコールを含んでいてもよい。
水性媒体の含有量は、粒子分散液全量に対して、50〜99.9質量%が好ましく、70〜99.9質量%がより好ましい。そして、粒子分散液を凝集試薬製造用粒子分散液とする場合は、80〜99.9質量%が更に好ましく、85〜99.9質量%が特に好ましい。一方、粒子分散液を凝集試薬とする場合は、95〜99.9質量%が更に好ましく、98〜99.9質量%が特に好ましい。
<Aqueous medium>
The aqueous medium may be any medium that can disperse the carrier particles, but preferably includes water. The content of water is preferably 40 to 100% by mass, more preferably 60 to 100% by mass, still more preferably 80 to 100% by mass, and particularly preferably 90 to 100% by mass with respect to the total amount of the aqueous medium.
The aqueous medium may be a buffer solution such as a Good buffer solution, a Tris buffer solution, a phosphate buffer solution, a glycine buffer solution, or an ammonia buffer solution.
The aqueous medium may contain a lower alcohol such as methanol, ethanol, isopropanol in addition to water and a buffer solution.
The content of the aqueous medium is preferably 50 to 99.9% by mass and more preferably 70 to 99.9% by mass with respect to the total amount of the particle dispersion. And when making a particle dispersion into the particle dispersion for aggregating reagent manufacture, 80-99.9 mass% is still more preferable, and 85-99.9 mass% is especially preferable. On the other hand, when the particle dispersion is used as an aggregating reagent, it is more preferably 95 to 99.9% by mass, and particularly preferably 98 to 99.9% by mass.

また、本発明の粒子分散液は、上記各成分の他に、界面活性剤、ブロッキング剤等を含んでいてもよい。   Moreover, the particle dispersion liquid of the present invention may contain a surfactant, a blocking agent and the like in addition to the above-described components.

<pH>
本発明の粒子分散液の25℃におけるpHは、3.0〜12.0の範囲が好ましく、凝集試薬として使用するためのものである場合は、5.0〜9.0の範囲がより好ましい。
<PH>
The pH at 25 ° C. of the particle dispersion of the present invention is preferably in the range of 3.0 to 12.0, and more preferably in the range of 5.0 to 9.0 when used as an agglutinating reagent. .

そして、後記実施例に記載のとおり、水性媒体を分散媒とする担体粒子の粒子分散液中にナフタレン骨格を有する低分子化合物を含有せしめ、これを用いて免疫凝集法による検出を行うことによって、検体中の標的物質の検出を高感度化できる。
したがって、本発明の粒子分散液は、凝集試薬として、或いは当該凝集試薬を製造するための素材(凝集試薬製造用粒子分散液)として有用である。なお、凝集試薬とは、免疫凝集法による検体中の標的物質の検出に使用される、粒子同士が凝集する際の濁度の変化量により、標的物質の量を定量する試薬を意味する。
本発明の粒子分散液を凝集試薬製造用粒子分散液とする場合、粒子分散液としては、保存安定性を考慮すると、標的物質と結合可能な物質が担持されていない担体粒子が担体粒子として分散したものが好ましい。一方、本発明の粒子分散液を凝集試薬とする場合、粒子分散液としては、標的物質との反応性を考慮すると、標的物質と結合可能な物質が担持された担体粒子が担体粒子として分散したものが好ましい。
そして、本発明の粒子分散液は、免疫凝集比濁法用凝集試薬、当該凝集試薬を製造するための素材として特に有用である。
Then, as described in Examples below, by incorporating a low molecular weight compound having a naphthalene skeleton in a particle dispersion of carrier particles using an aqueous medium as a dispersion medium, and performing detection by immunoaggregation using this, Sensitivity of the target substance in the sample can be increased.
Therefore, the particle dispersion of the present invention is useful as an agglutinating reagent or as a material for producing the agglutinating reagent (particle dispersion for producing an agglutinating reagent). The agglutinating reagent means a reagent that is used for detection of a target substance in a specimen by immunoagglutination and that quantifies the amount of the target substance based on the amount of change in turbidity when the particles aggregate.
When the particle dispersion liquid of the present invention is used as a particle dispersion liquid for producing an agglutinating reagent, the carrier particles that do not carry a substance that can bind to the target substance are dispersed as carrier particles in consideration of storage stability. Is preferred. On the other hand, when the particle dispersion liquid of the present invention is used as an agglutinating reagent, carrier particles carrying substances capable of binding to the target substance are dispersed as carrier particles in consideration of the reactivity with the target substance. Those are preferred.
The particle dispersion of the present invention is particularly useful as an agglutination reagent for immunoagglutination turbidimetry and a material for producing the agglutination reagent.

〔キット〕
本発明の免疫凝集法による検体中の標的物質の検出に用いるためのキットは、上記粒子分散液を備えるものである。当該キットに具備される場合、粒子分散液としては、標的物質との反応性を考慮すると、標的物質と結合可能な物質が担持された担体粒子が担体粒子として分散したものが好ましい。
〔kit〕
A kit for use in detection of a target substance in a specimen by the immunoaggregation method of the present invention comprises the above particle dispersion. When provided in the kit, the particle dispersion is preferably a dispersion in which carrier particles carrying a substance capable of binding to the target substance are dispersed as carrier particles in consideration of reactivity with the target substance.

本発明のキットは、上記粒子分散液(第2試薬とも称する)に加えて、ブロッキング剤及び免疫凝集促進剤から選ばれる1種以上を含有する試薬(第1試薬とも称する)を備えていてもよい。ブロッキング剤、免疫凝集促進剤としては、牛血清アルブミン等の生体由来の水溶性ポリマーや化学合成した水溶性ポリマー等が挙げられる。また、第1試薬は、上記と同様の水性媒体を含んでいてもよい。
また、本発明のキットは、上記第1試薬及び第2試薬の他に、陽性コントロール、陰性コントロール、血清希釈液等を備えていてもよい。陽性コントロール、陰性コントロールの媒体は、標的物質が含まれていない血清、生理食塩水の他、溶剤でもよい。当該溶剤としては上記水性媒体が挙げられる。
The kit of the present invention may include a reagent (also referred to as a first reagent) containing at least one selected from a blocking agent and an immune aggregation promoter in addition to the particle dispersion (also referred to as a second reagent). Good. Examples of the blocking agent and immune aggregation promoter include biologically derived water-soluble polymers such as bovine serum albumin and chemically synthesized water-soluble polymers. The first reagent may contain an aqueous medium similar to the above.
Moreover, the kit of this invention may be equipped with positive control, negative control, serum dilution liquid, etc. other than the said 1st reagent and 2nd reagent. The medium for positive control and negative control may be a solvent other than serum and physiological saline containing no target substance. Examples of the solvent include the above aqueous medium.

本発明のキットは、通常の免疫凝集法による検体中の標的物質の検出に用いるためのキットと同様にして、標的物質の検出方法に使用できる。また、常法に従い標的物質の濃度も測定できる。
そして、本発明のキットは、免疫凝集比濁法用キットとして特に有用である。
The kit of the present invention can be used in a method for detecting a target substance in the same manner as a kit for use in detecting a target substance in a specimen by a general immunoagglutination method. In addition, the concentration of the target substance can be measured according to a conventional method.
The kit of the present invention is particularly useful as a kit for immunoagglutination turbidimetry.

〔検出方法〕
本発明の免疫凝集法による検体中の標的物質の検出方法は、標的物質と結合可能な物質が担持された担体粒子と、検体とを、ナフタレン骨格を有する低分子化合物の存在下で接触させる工程を含むことを特徴とするものである。本検出方法は、ナフタレン骨格を有する低分子化合物の存在下で行う以外は、担体粒子と検体を混合する等、常法の検出方法と同様にして行えばよい。なお、ナフタレン骨格を有する低分子化合物としては、上記粒子分散液に含まれるものと同様のものが挙げられ、その使用量としては、上記粒子分散液における担体粒子固形分100質量部に対する含有量と同様の範囲が好ましい。
[Detection method]
The method for detecting a target substance in a specimen by the immunoaggregation method of the present invention is a step of bringing a carrier particle carrying a substance capable of binding to the target substance into contact with the specimen in the presence of a low molecular compound having a naphthalene skeleton. It is characterized by including. This detection method may be carried out in the same manner as a conventional detection method, for example, by mixing carrier particles and a specimen, except that it is performed in the presence of a low molecular compound having a naphthalene skeleton. In addition, examples of the low molecular weight compound having a naphthalene skeleton include the same compounds as those contained in the particle dispersion, and the amount used thereof is the content with respect to 100 parts by mass of carrier particle solid content in the particle dispersion. A similar range is preferred.

検体は、標的物質を含むもの又は標的物質を含む可能性があるようなものであればよく、具体的には、血清や血漿、尿、唾液等の各種生物学的液体サンプル、糞便や食品の検体粉砕物等が挙げられる。また、pH緩衝液、タンパク質、アミノ酸等で検体を希釈した検体希釈液でもよい。   The specimen only needs to contain the target substance or may contain the target substance. Specifically, various biological liquid samples such as serum, plasma, urine, saliva, feces and food Examples include pulverized specimens. Further, it may be a sample diluent obtained by diluting a sample with a pH buffer solution, protein, amino acid or the like.

担体粒子と検体との接触は、pH4〜10の範囲で行うのが好ましい。また、接触温度は通常25〜45℃の範囲であり、接触時間は通常1〜20分である。
また、担体粒子と検体との接触は、ナフタレン骨格を有する低分子化合物の存在下で行われるものであるが、ナフタレン骨格を有する低分子化合物とともに溶剤を使用するのが好ましい。溶剤としては、水性媒体として例示したものの他、エタノール、メタノール、イソプロパノール等の低級アルコール;アセトン、メチルエチルケトン、メチルイソブチルケトン等のケトン;酢酸エチル、酢酸ブチル等の酢酸エステル;ジメチルホルムアミド等のアミド;ジメチルスルホキシド等のスルホキシドが挙げられ、これらのうち1種を単独でまたは2種以上を組み合わせてもよい。
The contact between the carrier particles and the specimen is preferably performed in the pH range of 4-10. The contact temperature is usually in the range of 25 to 45 ° C., and the contact time is usually 1 to 20 minutes.
In addition, the contact between the carrier particles and the specimen is performed in the presence of a low molecular compound having a naphthalene skeleton, but it is preferable to use a solvent together with the low molecular compound having a naphthalene skeleton. Examples of the solvent include those exemplified as an aqueous medium, lower alcohols such as ethanol, methanol, and isopropanol; ketones such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; acetate esters such as ethyl acetate and butyl acetate; amides such as dimethylformamide; dimethyl Examples thereof include sulfoxides such as sulfoxide, and one of these may be used alone or two or more of them may be combined.

そして、上記担体粒子と検体との接触の結果として生じる凝集反応を光学的に検出することで、検体中の標的物質が検出され、更に標的物質の濃度も測定できる。凝集反応の光学的な検出は、散乱光強度、透過光強度、吸光度等を検出できる光学機器を用いて常法に従い行えばよい。本発明の検出方法は、免疫凝集比濁法による検出に特に有用である。   The target substance in the specimen is detected by optically detecting the agglutination reaction that occurs as a result of contact between the carrier particles and the specimen, and the concentration of the target substance can also be measured. The optical detection of the agglutination reaction may be performed according to a conventional method using an optical instrument that can detect scattered light intensity, transmitted light intensity, absorbance, and the like. The detection method of the present invention is particularly useful for detection by immunoagglutination turbidimetry.

以下、実施例を挙げて本発明を詳細に説明するが、本発明はこれら実施例に限定されるものではない。なお、粒子の平均粒径(体積平均粒子径)は、ナノトラック粒度分布測定装置UPA−EX150(日機装(株)製)にて測定した。   EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated in detail, this invention is not limited to these Examples. In addition, the average particle diameter (volume average particle diameter) of the particles was measured with a nanotrack particle size distribution analyzer UPA-EX150 (manufactured by Nikkiso Co., Ltd.).

〔調製例1 ラテックス粒子の調製〕
冷却管、温度調節器及び攪拌装置を備えた1Lの4口フラスコに、水100質量部と、ドデシルベンゼンスルホン酸ナトリウム0.1質量部と、スチレン18質量部と、メタクリル酸2質量部を入れ、毎分200回転で攪拌しながら、過硫酸カリウム1質量部を水50質量部に溶解したものを加えた。温度が75℃になってから2時間反応を行ったのち、スチレン75質量部と、メタクリル酸5質量部と、ドデシルベンゼンスルホン酸ナトリウム0.6質量部と、水200質量部からなる単量体エマルジョンを5時間掛けて滴下し、引き続き4時間重合を続け、重合体粒子の水分散液を得た。その後、この重合体粒子の水分散液を精製し、粒子の固形分を10質量%に調整した。この粒子水分散液をシード粒子水分散液(A)とする。シード粒子水分散液(A)に含まれるシード粒子の平均粒径は0.15μmであった。
上記シード粒子水分散液(A)100質量部(粒子固形分として10質量部、水として90質量部)を上記と同様の4つ口フラスコに入れ、毎分200回転で攪拌しながら75℃に上昇させ、過硫酸カリウム1.5質量部を水70質量部に溶解したものを投入し、スチレン89質量部と、メタクリル酸1質量部と、ドデシルベンゼンスルホン酸ナトリウム2質量部と、水400質量部からなる単量体エマルジョンを5時間掛けて滴下し、その後3時間重合させた。
以上で得られた粒子をラテックス粒子(B)とする。ラテックス粒子(B)の平均粒径は約0.3μmであった。
[Preparation Example 1 Preparation of Latex Particles]
In a 1 L four-necked flask equipped with a condenser, a temperature controller, and a stirrer, 100 parts by mass of water, 0.1 part by mass of sodium dodecylbenzenesulfonate, 18 parts by mass of styrene, and 2 parts by mass of methacrylic acid are placed. While stirring at 200 revolutions per minute, 1 part by weight of potassium persulfate dissolved in 50 parts by weight of water was added. After reacting for 2 hours after the temperature reaches 75 ° C., a monomer comprising 75 parts by mass of styrene, 5 parts by mass of methacrylic acid, 0.6 part by mass of sodium dodecylbenzenesulfonate, and 200 parts by mass of water The emulsion was added dropwise over 5 hours and polymerization was continued for 4 hours to obtain an aqueous dispersion of polymer particles. Thereafter, the aqueous dispersion of the polymer particles was purified, and the solid content of the particles was adjusted to 10% by mass. This particle aqueous dispersion is referred to as seed particle aqueous dispersion (A). The average particle size of the seed particles contained in the seed particle aqueous dispersion (A) was 0.15 μm.
100 parts by mass of the above seed particle aqueous dispersion (A) (10 parts by mass as particle solids and 90 parts by mass as water) are put into a four-necked flask similar to the above and heated to 75 ° C. while stirring at 200 rpm. The mixture was charged with 1.5 parts by mass of potassium persulfate dissolved in 70 parts by mass of water, 89 parts by mass of styrene, 1 part by mass of methacrylic acid, 2 parts by mass of sodium dodecylbenzenesulfonate, and 400 parts by mass of water. Part of the monomer emulsion was added dropwise over 5 hours and then polymerized for 3 hours.
The particles obtained above are referred to as latex particles (B). The average particle size of the latex particles (B) was about 0.3 μm.

〔調製例2 第1試薬の調製〕
牛血清アルブミン(BSA)0.1質量%含有10mM HEPES緩衝液(pH7.5)を作製した。これを「第1試薬」とする。
[Preparation Example 2 Preparation of First Reagent]
A 10 mM HEPES buffer (pH 7.5) containing 0.1% by mass of bovine serum albumin (BSA) was prepared. This is referred to as “first reagent”.

〔実施例1 第2試薬の調製(1)〕
調製例1で得られたラテックス粒子(B)を遠心分離、再懸濁にて精製し、粒子固形分濃度が10質量%となるように水に加えた。この粒子含有液1mLと、HEPES緩衝液(0.05M、pH7.5)9mLとを混合(粒子固形分濃度=1質量%)し、これに2−アセチルナフタレン1質量%含有エタノール溶液を10μL(2−アセチルナフタレンが粒子固形分100質量部に対して0.1質量部となる量)添加した。この分散液を、第2試薬(凝集試薬)製造用分散液(C)とする。
上記第2試薬(凝集試薬)製造用分散液(C)に、1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド塩酸塩(同仁化学社製)を、最終濃度が0.05質量%となるように添加した。更に、この粒子分散液に、抗CRP(C反応性蛋白)抗体(ウサギ)の10mg/mL水溶液を0.5mL加えて室温で3時間攪拌し、抗体を粒子の表面に結合させた。
その後、この粒子分散液にBSA1質量%水溶液を0.5mL加え、室温で10時間回転攪拌した後、15,000rpmにて15分間遠心分離し、粒子を沈殿として回収した。
次いで、HEPES緩衝液(0.05M、pH7.5)10mLに上記粒子を再懸濁させ、超音波で10分間分散させた。この懸濁液を再び15,000rpmにて15分間遠心分離し、粒子を沈殿として回収した後、上記再懸濁及び分散の操作をもう一度繰り返した。これに、BSA0.02質量%含有10mM HEPES緩衝液(pH7.5)を190mL加えて粒子固形分が0.05質量%となるように調整した後、超音波で10分間分散させ、0.8μmディスクフィルターに通した。
上記の操作により、BSAがブロッキング剤としてコーティングされた抗体結合ラテックス粒子の分散液を得た。これを「第2試薬(1)」とする。第2試薬(1)に含まれる2−アセチルナフタレンの含有量は、粒子固形分100質量部に対して約0.1質量部であった。
[Example 1 Preparation of second reagent (1)]
The latex particles (B) obtained in Preparation Example 1 were purified by centrifugation and resuspension, and added to water so that the particle solid content concentration was 10% by mass. 1 mL of this particle-containing solution and 9 mL of HEPES buffer (0.05 M, pH 7.5) were mixed (particle solid content concentration = 1% by mass), and 10 μL of an ethanol solution containing 1% by mass of 2-acetylnaphthalene was added thereto ( 2-acetylnaphthalene was added in an amount of 0.1 parts by mass with respect to 100 parts by mass of the particle solid content). This dispersion is designated as dispersion (C) for producing a second reagent (aggregation reagent).
In the dispersion (C) for producing the second reagent (aggregation reagent), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (manufactured by Dojin Chemical Co., Ltd.) was added at a final concentration of 0.05% by mass. It added so that it might become. Furthermore, 0.5 mL of a 10 mg / mL aqueous solution of anti-CRP (C-reactive protein) antibody (rabbit) was added to this particle dispersion and stirred at room temperature for 3 hours to bind the antibody to the particle surface.
Thereafter, 0.5 mL of a 1% by weight aqueous solution of BSA was added to the particle dispersion, and the mixture was rotated and stirred at room temperature for 10 hours, and then centrifuged at 15,000 rpm for 15 minutes to collect particles as a precipitate.
The particles were then resuspended in 10 mL of HEPES buffer (0.05 M, pH 7.5) and dispersed with ultrasound for 10 minutes. This suspension was centrifuged again at 15,000 rpm for 15 minutes to collect the particles as a precipitate, and then the above resuspension and dispersion operations were repeated once more. To this, 190 mL of 10 mM HEPES buffer solution (pH 7.5) containing 0.02% by mass of BSA was added to adjust the particle solid content to 0.05% by mass, and then dispersed ultrasonically for 10 minutes, 0.8 μm I passed the disc filter.
By the above operation, a dispersion of antibody-bound latex particles coated with BSA as a blocking agent was obtained. This is designated as “second reagent (1)”. The content of 2-acetylnaphthalene contained in the second reagent (1) was about 0.1 parts by mass with respect to 100 parts by mass of the particle solid content.

〔実施例2 第2試薬の調製(2)〕
実施例1において、2−アセチルナフタレン1質量%含有エタノール溶液を10μL添加する代わりに、2−アセチルナフタレン10質量%含有エタノール溶液を5μL(粒子固形分100質量部対比で2−アセチルナフタレン0.5質量部)添加した以外は同様に一連の操作を行い、第2試薬(2)を得た。第2試薬(2)に含まれる2−アセチルナフタレンの含有量は、粒子固形分100質量部に対して約0.5質量部であった。
[Example 2 Preparation of second reagent (2)]
In Example 1, instead of adding 10 μL of an ethanol solution containing 1% by mass of 2-acetylnaphthalene, 5 μL of an ethanol solution containing 10% by mass of 2-acetylnaphthalene (0.5% of 2-acetylnaphthalene in terms of 100 parts by mass of particle solid content) was added. (Mass part) A series of operations were performed in the same manner except that the second reagent (2) was obtained. The content of 2-acetylnaphthalene contained in the second reagent (2) was about 0.5 parts by mass with respect to 100 parts by mass of the particle solid content.

〔実施例3 第2試薬の調製(3)〕
実施例1において、2−アセチルナフタレン1質量%含有エタノール溶液を10μL添加する代わりに、2−アセチルナフタレン10質量%含有エタノール溶液を10μL(粒子固形分100質量部対比で2−アセチルナフタレン1.0質量部)添加した以外は同様に一連の操作を行い、第2試薬(3)を得た。第2試薬(3)に含まれる2−アセチルナフタレンの含有量は、粒子固形分100質量部に対して約1.0質量部であった。
[Example 3 Preparation of second reagent (3)]
In Example 1, instead of adding 10 μL of an ethanol solution containing 1% by mass of 2-acetylnaphthalene, 10 μL of an ethanol solution containing 10% by mass of 2-acetylnaphthalene (2-acetylnaphthalene 1.0 in terms of 100 parts by mass of particle solid content) was added. (Mass part) A series of operations were performed in the same manner except that the second reagent (3) was obtained. The content of 2-acetylnaphthalene contained in the second reagent (3) was about 1.0 part by mass with respect to 100 parts by mass of the particle solid content.

〔実施例4 第2試薬の調製(4)〕
実施例1において、2−アセチルナフタレン1質量%含有エタノール溶液を10μL添加する代わりに、2−アセチルナフタレン10質量%含有エタノール溶液を20μL(粒子固形分100質量部対比で2−アセチルナフタレン2.0質量部)添加した以外は同様に一連の操作を行い、第2試薬(4)を得た。第2試薬(4)に含まれる2−アセチルナフタレンの含有量は、粒子固形分100質量部に対して約2.0質量部であった。
[Example 4 Preparation of Second Reagent (4)]
In Example 1, instead of adding 10 μL of an ethanol solution containing 1% by mass of 2-acetylnaphthalene, 20 μL of an ethanol solution containing 10% by mass of 2-acetylnaphthalene (in contrast to 100 parts by mass of particle solid content, 2.0-acetylnaphthalene 2.0 A second reagent (4) was obtained in the same manner as described above except that (mass parts) was added. The content of 2-acetylnaphthalene contained in the second reagent (4) was about 2.0 parts by mass with respect to 100 parts by mass of the particle solid content.

〔実施例5 第2試薬の調製(5)〕
実施例1において、2−アセチルナフタレン1質量%含有エタノール溶液を10μL添加する代わりに、2−アセチルナフタレン10質量%含有エタノール溶液を80μL(粒子固形分100質量部対比で2−アセチルナフタレン8.0質量部)添加した以外は同様に一連の操作を行い、第2試薬(5)を得た。第2試薬(5)に含まれる2−アセチルナフタレンの含有量は、粒子固形分100質量部に対して約8.0質量部であった。
[Example 5: Preparation of second reagent (5)]
In Example 1, instead of adding 10 μL of an ethanol solution containing 1% by mass of 2-acetylnaphthalene, 80 μL of an ethanol solution containing 10% by mass of 2-acetylnaphthalene (compared to 100 parts by mass of particle solid content of 8.0% 2-acetylnaphthalene). (Mass part) A series of operations were performed in the same manner except that the second reagent (5) was obtained. The content of 2-acetylnaphthalene contained in the second reagent (5) was about 8.0 parts by mass with respect to 100 parts by mass of the particle solid content.

〔実施例6 第2試薬の調製(6)〕
実施例1において、2−アセチルナフタレン1質量%含有エタノール溶液を、1−アセチルナフタレン1質量%含有エタノール溶液に替えた以外は同様に一連の操作を行い、第2試薬(6)を得た。第2試薬(6)に含まれる1−アセチルナフタレンの含有量は、粒子固形分100質量部に対して約0.1質量部であった。
[Example 6: Preparation of second reagent (6)]
In Example 1, a series of operations was performed in the same manner except that the ethanol solution containing 1% by mass of 2-acetylnaphthalene was replaced with an ethanol solution containing 1% by mass of 1-acetylnaphthalene, to obtain a second reagent (6). The content of 1-acetylnaphthalene contained in the second reagent (6) was about 0.1 parts by mass with respect to 100 parts by mass of the particle solid content.

〔実施例7 第2試薬の調製(7)〕
実施例2において、2−アセチルナフタレン10質量%含有エタノール溶液を、1−アセチルナフタレン10質量%含有エタノール溶液に替えた以外は同様に一連の操作を行い、第2試薬(7)を得た。第2試薬(7)に含まれる1−アセチルナフタレンの含有量は、粒子固形分100質量部に対して約0.5質量部であった。
[Example 7: Preparation of second reagent (7)]
In Example 2, a series of operations was performed in the same manner except that the ethanol solution containing 10% by mass of 2-acetylnaphthalene was replaced with the ethanol solution containing 10% by mass of 1-acetylnaphthalene, to obtain a second reagent (7). The content of 1-acetylnaphthalene contained in the second reagent (7) was about 0.5 parts by mass with respect to 100 parts by mass of the particle solid content.

〔実施例8 第2試薬の調製(8)〕
実施例3において、2−アセチルナフタレン10質量%含有エタノール溶液を、1−アセチルナフタレン10質量%含有エタノール溶液に替えた以外は同様に一連の操作を行い、第2試薬(8)を得た。第2試薬(8)に含まれる1−アセチルナフタレンの含有量は、粒子固形分100質量部に対して約1.0質量部であった。
[Example 8: Preparation of second reagent (8)]
In Example 3, a series of operations was performed in the same manner except that the ethanol solution containing 10% by mass of 2-acetylnaphthalene was replaced with an ethanol solution containing 10% by mass of 1-acetylnaphthalene, to obtain a second reagent (8). The content of 1-acetylnaphthalene contained in the second reagent (8) was about 1.0 part by mass with respect to 100 parts by mass of the particle solid content.

〔比較例1 第2試薬の調製(9)〕
実施例1において、2−アセチルナフタレン1質量%含有エタノール溶液を10μL添加する代わりに、エタノールを20μL添加した以外は同様に一連の操作を行い、第2試薬(9)を得た。
[Comparative Example 1 Preparation of Second Reagent (9)]
In Example 1, instead of adding 10 μL of an ethanol solution containing 1% by mass of 2-acetylnaphthalene, a series of operations were performed in the same manner except that 20 μL of ethanol was added to obtain a second reagent (9).

〔比較例2 第2試薬の調製(10)〕
実施例1において、2−アセチルナフタレン1質量%含有エタノール溶液を10μL添加する代わりに、ポリエチレングリコール(分子量:20000)5質量%含有水溶液を40μL(粒子固形分100質量部対比でポリエチレングリコール2.0質量部)添加した以外は同様に一連の操作を行い、第2試薬(10)を得た。
[Comparative Example 2 Preparation of Second Reagent (10)]
In Example 1, instead of adding 10 μL of an ethanol solution containing 1% by mass of 2-acetylnaphthalene, 40 μL of an aqueous solution containing 5% by mass of polyethylene glycol (molecular weight: 20000) (as compared with 100 parts by mass of particle solid content of polyethylene glycol 2.0) (Mass part) A series of operations were performed in the same manner except that the second reagent (10) was obtained.

〔試験例1 ラテックス凝集反応の評価〕
免疫ラテックス凝集測定においては、日立7180型自動分析装置を使用した。測定波長は570nm、測定温度は37℃とした。生理食塩水(CRP抗原濃度0mg/dL)又はCRP抗原の生理食塩水希釈液(CRP抗原濃度:0.01mg/dL又は0.04mg/dL)を測定セルに3μL加えた後、調製例2で得た第1試薬150μLをセルに加えて均一攪拌した後、5分間保持した。
その後、実施例1で得た第2試薬(1)150μLをセルに加えて均一攪拌した後、50秒経過時の吸光度と200秒経過時の吸光度との差を計測した。
また、実施例1で得た第2試薬(1)を、第2試薬(2)〜(10)に変更する以外は上記と同様にして吸光度差の計測を行った。
試験結果を表1に示す。
[Test Example 1 Evaluation of Latex Aggregation Reaction]
In the measurement of immune latex agglutination, Hitachi 7180 type automatic analyzer was used. The measurement wavelength was 570 nm and the measurement temperature was 37 ° C. After adding 3 μL of physiological saline (CRP antigen concentration 0 mg / dL) or CRP antigen physiological saline dilution (CRP antigen concentration: 0.01 mg / dL or 0.04 mg / dL) to the measurement cell, 150 μL of the obtained first reagent was added to the cell and stirred uniformly, and then held for 5 minutes.
Thereafter, 150 μL of the second reagent (1) obtained in Example 1 was added to the cell and stirred uniformly, and then the difference between the absorbance after 50 seconds and the absorbance after 200 seconds was measured.
Further, the absorbance difference was measured in the same manner as described above except that the second reagent (1) obtained in Example 1 was changed to the second reagents (2) to (10).
The test results are shown in Table 1.

〔試験例2 保存安定性試験〕
実施例1〜8で得た第2試薬(1)〜(8)を、第2試薬の調製から1週間25℃にて保管し、粒子の沈殿の有無を目視にて確認し、以下の基準で評価した。試験結果を表1に示す。
(評価基準)
○:粒子の沈殿が確認できなかった
×:粒子の沈殿が確認された
[Test Example 2 Storage Stability Test]
The second reagents (1) to (8) obtained in Examples 1 to 8 were stored at 25 ° C. for one week from the preparation of the second reagent, and the presence or absence of particle precipitation was visually confirmed. It was evaluated with. The test results are shown in Table 1.
(Evaluation criteria)
○: Precipitation of particles could not be confirmed ×: Precipitation of particles was confirmed

Figure 0006442291
Figure 0006442291

表1に示す試験例1の結果から、ナフタレン骨格を有する低分子化合物が、ラテックス凝集反応を大きく促進させ、検出を高感度化できることがわかった。   From the results of Test Example 1 shown in Table 1, it was found that the low molecular weight compound having a naphthalene skeleton can greatly accelerate the latex agglutination reaction and increase the detection sensitivity.

Claims (11)

水性媒体を分散媒とする担体粒子の粒子分散液であって、アセチルナフタレンを含有する、粒子分散液。 A particle dispersion liquid of carrier particles containing an aqueous medium as a dispersion medium and containing acetylnaphthalene . 前記水性媒体が、水を含むものである、請求項1に記載の粒子分散液。   The particle dispersion according to claim 1, wherein the aqueous medium contains water. 前記アセチルナフタレンの含有量が、担体粒子固形分100質量部に対して、0.01〜10質量部である、請求項1又は2に記載の粒子分散液。 The content of acetyl naphthalene, with respect to the support particles to 100 parts by weight of solid content, is 0.01 to 10 parts by weight, the particle dispersion according to claim 1 or 2. 前記アセチルナフタレンの含有量が、担体粒子固形分100質量部に対して、0.01〜5質量部である、請求項1〜のいずれか1項に記載の粒子分散液。 The content of acetyl naphthalene, with respect to the support particles to 100 parts by weight of solid content, 0.01 to 5 parts by weight, the particle dispersion liquid according to any one of claims 1-3. 前記担体粒子が、ラテックス粒子である、請求項1〜のいずれか1項に記載の粒子分散液。 Wherein the carrier particles are latex particles, particle dispersion liquid according to any one of claims 1-4. 前記担体粒子が、アリール基を有するモノマーを含むモノマー成分に由来するポリマー粒子である、請求項1〜のいずれか1項に記載の粒子分散液。 Wherein the carrier particles are polymer particles derived from a monomer component containing a monomer having an aryl group, particle dispersion liquid according to any one of claims 1-5. 前記担体粒子が、標的物質と結合可能な物質が担持された担体粒子である、請求項1〜のいずれか1項に記載の粒子分散液。 The particle dispersion according to any one of claims 1 to 6 , wherein the carrier particles are carrier particles on which a substance capable of binding to a target substance is supported. 前記標的物質と結合可能な物質が、標的物質に対する抗原又は抗体である、請求項に記載の粒子分散液。 The particle dispersion liquid according to claim 7 , wherein the substance capable of binding to the target substance is an antigen or an antibody against the target substance. 凝集試薬として使用するためのものである、請求項又はに記載の粒子分散液。 The particle dispersion according to claim 7 or 8 , which is for use as an agglutinating reagent. 免疫凝集法による検体中の標的物質の検出に用いるためのキットであって、請求項1〜のいずれか1項に記載の粒子分散液を備える、キット。 A kit for use in detection of a target substance in a specimen by immunoagglutination, comprising the particle dispersion according to any one of claims 1 to 9 . 免疫凝集法による検体中の標的物質の検出方法であって、標的物質と結合可能な物質が担持された担体粒子と、検体とを、アセチルナフタレンの存在下で接触させる工程を含むことを特徴とする、検出方法。 A method for detecting a target substance in a specimen by immunoagglutination, comprising a step of contacting a carrier particle carrying a substance capable of binding to the target substance and the specimen in the presence of acetylnaphthalene Detection method.
JP2015001216A 2015-01-07 2015-01-07 Particle dispersion, kit for use in detection of target substance, and target substance detection method Active JP6442291B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015001216A JP6442291B2 (en) 2015-01-07 2015-01-07 Particle dispersion, kit for use in detection of target substance, and target substance detection method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015001216A JP6442291B2 (en) 2015-01-07 2015-01-07 Particle dispersion, kit for use in detection of target substance, and target substance detection method

Publications (2)

Publication Number Publication Date
JP2016125948A JP2016125948A (en) 2016-07-11
JP6442291B2 true JP6442291B2 (en) 2018-12-19

Family

ID=56357859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015001216A Active JP6442291B2 (en) 2015-01-07 2015-01-07 Particle dispersion, kit for use in detection of target substance, and target substance detection method

Country Status (1)

Country Link
JP (1) JP6442291B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6224217B1 (en) * 2016-12-27 2017-11-01 Jsr株式会社 How to store latex particle dispersion
JP7406327B2 (en) * 2019-08-23 2023-12-27 キヤノン株式会社 Particles, particles for agglutination methods, reagents containing the same, kits, and detection methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07113640B2 (en) * 1986-07-07 1995-12-06 東ソー株式会社 Carrier for immobilizing protein and method for producing the same
JPH01310667A (en) * 1988-06-08 1989-12-14 Nissho Corp Blood separator
JPH0649100A (en) * 1992-05-06 1994-02-22 Eastman Kodak Co Method for bonding compound to carboxylated base
JPH09101308A (en) * 1995-10-05 1997-04-15 Sekisui Chem Co Ltd Treponema pallidum antibody measuring method
JPH10282102A (en) * 1997-04-11 1998-10-23 Sekisui Chem Co Ltd Method and kit for measurement
JP2003294753A (en) * 2002-04-01 2003-10-15 Kyokuto Seiyaku Kogyo Kk Agglutination reaction sensitizer, reagent for immunoassay, and method of immunoassay
WO2007074860A1 (en) * 2005-12-28 2007-07-05 Sekisui Medical Co., Ltd. Reagent for measuring aggregation and method of measuring aggregation
JP2008170422A (en) * 2006-12-15 2008-07-24 Fujifilm Corp Immunoassay method
JP2009139214A (en) * 2007-12-06 2009-06-25 Konica Minolta Holdings Inc Polymer particulate dispersed object, composition for measurement including it, and detecting method of material to be tested using it
JP5170806B2 (en) * 2011-03-31 2013-03-27 積水メディカル株式会社 Latex particles for measuring reagent, sensitized latex particles, and measuring reagent for immunoturbidimetric method

Also Published As

Publication number Publication date
JP2016125948A (en) 2016-07-11

Similar Documents

Publication Publication Date Title
WO2002018953A1 (en) Highly reproducible agglutination immunoassay method and reagents
US9465033B2 (en) Latex particles for agglutination assay
JP5170806B2 (en) Latex particles for measuring reagent, sensitized latex particles, and measuring reagent for immunoturbidimetric method
JP4853666B2 (en) Target substance detection method, mixed particles, and target substance detection reagent
JP5026251B2 (en) Detection method and quantification method of detection target
JP6442291B2 (en) Particle dispersion, kit for use in detection of target substance, and target substance detection method
WO2021075426A1 (en) Particles and method for producing particles
JP5288349B2 (en) Immunological analysis reagent and immunological analysis method
US8227263B2 (en) Process for producing polymer particles
JP6085983B2 (en) Blocking agent, carrier on which antigen or antibody to target substance is immobilized, in vitro diagnostic reagent and kit containing the same, and method for detecting target substance
JP7360846B2 (en) Sample testing particles and their manufacturing method
JP2004325414A (en) Method and kit for measuring immunity
JP2001074742A (en) Latex immunity nephelometry measurement method and kit
JP2021066841A (en) Particle and method of producing the particle
JP4151771B2 (en) Immunological agglutination reagent
US10557848B2 (en) Polymer microparticle for carrying physiologically active substance and method for preparing same
JP6051903B2 (en) Aggregation accelerator for latex agglutination reaction, target substance detection method and kit for use in target substance detection
JP2003277455A (en) Method for producing polymer particle, polymer particle and carrier for physiologically active substance
JPH02114180A (en) Analytic reagent, element and latex particle for method
JPS6366464A (en) Carrier latex for diagnosing reagent
JPH08278308A (en) Immunoassay method
JP3452218B2 (en) Polymer latex for diagnostic reagents and diagnostic agents
JP2004117068A (en) Immunoassay reagent and immunoassay method
WO2017090721A1 (en) Method of determining quantity of objects to be detected in specimen
JP2006153590A (en) Immunological measuring method and reagent kit

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181126

R150 Certificate of patent or registration of utility model

Ref document number: 6442291

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250